Abstract
Since recombinant gene technology was established to provide rare important regulatory proteins as recombinant molecules, cytokine therapies have widely developed and enormously contributed to the treatment of various diseases, nevertheless, it has been revealed that recombinant therapeutic molecules are not always perfect because of sideeffects related to pharmacological functions of cytokines and / or potential antigenicity observed in some clinical cases. Although studies on the antigenicity of recombinant proteins have initiated, and observations in clinical studies have been accumulated over this decade, mechanisms of the autoantibody production are not clarified yet. Among various hematopoietic growth factors introduced into clinical trials, this report summarizes current issues of autoantibodies to primary regulators for terminal hematopoiesis.
Keywords: anemia, autoantibody, cytokine, erythropoietin, g-csf, hematopoietic growth factor, peg-rhumgdf, thrombocytopenia, thrombopoietin
Current Pharmaceutical Design
Title: Therapeutically-induced Autoantibodies in Patients Treated with Recombinant Hematopoietic Growth Factors: A Brief Summary
Volume: 9 Issue: 14
Author(s): Takashi Kato and Hiroshi Miyazaki
Affiliation:
Keywords: anemia, autoantibody, cytokine, erythropoietin, g-csf, hematopoietic growth factor, peg-rhumgdf, thrombocytopenia, thrombopoietin
Abstract: Since recombinant gene technology was established to provide rare important regulatory proteins as recombinant molecules, cytokine therapies have widely developed and enormously contributed to the treatment of various diseases, nevertheless, it has been revealed that recombinant therapeutic molecules are not always perfect because of sideeffects related to pharmacological functions of cytokines and / or potential antigenicity observed in some clinical cases. Although studies on the antigenicity of recombinant proteins have initiated, and observations in clinical studies have been accumulated over this decade, mechanisms of the autoantibody production are not clarified yet. Among various hematopoietic growth factors introduced into clinical trials, this report summarizes current issues of autoantibodies to primary regulators for terminal hematopoiesis.
Export Options
About this article
Cite this article as:
Kato Takashi and Miyazaki Hiroshi, Therapeutically-induced Autoantibodies in Patients Treated with Recombinant Hematopoietic Growth Factors: A Brief Summary, Current Pharmaceutical Design 2003; 9 (14) . https://dx.doi.org/10.2174/1381612033455044
DOI https://dx.doi.org/10.2174/1381612033455044 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nanotechnologies for Anti-Inflammatory RNAi-Based Gene Silencing Strategies
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Inflammation and Antiangiogenesis in Cancer
Current Medicinal Chemistry Sigma-2 Receptor as a Potential Drug Target
Current Medicinal Chemistry Breast Cancer Segmentation Recognition Using Explored DCT-DWT based Compression
Recent Patents on Engineering Design, Synthesis, In vitro Cytotoxic Activity Evaluation, and Study of Apoptosis Inducing Effect of New Styrylimidazo[1,2-a]Pyridines as Potent Anti-Breast Cancer Agents
Anti-Cancer Agents in Medicinal Chemistry Heavy Metals and Epigenetic Alterations in Brain Tumors
Current Genomics Medicinal Research Progress of Natural Coumarin and its Derivatives
The Natural Products Journal Natural Polyphenols and their Synthetic Analogs as Emerging Anticancer Agents
Current Drug Targets LRIGs: A Prognostically Significant Family with Emerging Therapeutic Competence against Cancers
Current Cancer Drug Targets Anticancer Properties of Flavonoids: Roles in Various Stages of Carcinogenesis
Cardiovascular & Hematological Agents in Medicinal Chemistry miRNA 21: Diagnostic Prognostic and Therapeutic Marker for Oral Cancer
MicroRNA Selective Photodynamic Effects on Breast Cancer Cells Provided by p123 Pluronic®- Based Nanoparticles Modulating Hypericin Delivery
Anti-Cancer Agents in Medicinal Chemistry Methylglyoxal and Advanced Glycation Endproducts: New Therapeutic Horizons?
Recent Patents on Cardiovascular Drug Discovery Computational Analysis of the Interaction between Ligand-Receptor Pairs
Current Pharmaceutical Design FAT10: Function and Relationship with Cancer
Current Molecular Pharmacology The Effect of Drugs on the Labeling of Blood Elements with Technetium-99m
Current Pharmaceutical Design The Effects of Caffeine on the Cholinergic System
Mini-Reviews in Medicinal Chemistry Inhibition of Disulfide Reductases as a Therapeutic Strategy
Current Enzyme Inhibition Cancer Stem Cells of Head and Neck Squamous Cell Carcinoma
Current Cancer Therapy Reviews Mechanisms of Resistance to Photodynamic Therapy
Current Medicinal Chemistry